Chimerix Inc. (NASDAQ:CMRX) has been given a consensus rating of “Hold” by the fifteen brokerages that are currently covering the firm. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.65.

A number of equities research analysts recently commented on CMRX shares. Zacks Investment Research cut shares of Chimerix from a “buy” rating to a “hold” rating in a report on Tuesday, October 18th. Piper Jaffray Cos. set a $12.00 price target on shares of Chimerix and gave the stock a “buy” rating in a report on Thursday, August 18th. FBR & Co reaffirmed a “hold” rating on shares of Chimerix in a report on Sunday, October 30th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $7.00 price target on shares of Chimerix in a report on Tuesday, August 9th.

In other news, insider M Michelle Berrey purchased 22,417 shares of Chimerix stock in a transaction dated Monday, August 29th. The stock was purchased at an average cost of $4.47 per share, for a total transaction of $100,203.99. Following the transaction, the insider now directly owns 281,238 shares of the company’s stock, valued at $1,257,133.86. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John M. Leonard sold 5,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.03, for a total transaction of $25,150.00. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CMRX. California State Teachers Retirement System raised its position in Chimerix by 0.7% in the third quarter. California State Teachers Retirement System now owns 90,116 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 600 shares during the period. Teachers Advisors Inc. raised its position in shares of Chimerix by 0.9% in the second quarter. Teachers Advisors Inc. now owns 69,684 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 610 shares during the period. BlackRock Investment Management LLC raised its position in shares of Chimerix by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 187,449 shares of the biopharmaceutical company’s stock valued at $1,038,000 after buying an additional 1,477 shares during the period. Raymond James & Associates raised its position in shares of Chimerix by 6.9% in the second quarter. Raymond James & Associates now owns 27,083 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,757 shares during the period. Finally, BlackRock Advisors LLC raised its position in shares of Chimerix by 19.4% in the third quarter. BlackRock Advisors LLC now owns 22,213 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 3,611 shares during the period. Hedge funds and other institutional investors own 68.63% of the company’s stock.

Shares of Chimerix (NASDAQ:CMRX) traded up 0.98% during midday trading on Wednesday, hitting $5.15. The company’s stock had a trading volume of 201,871 shares. The firm’s market cap is $238.52 million. Chimerix has a 52-week low of $3.49 and a 52-week high of $42.24. The stock’s 50 day moving average is $4.65 and its 200-day moving average is $4.55.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Chimerix had a negative return on equity of 32.09% and a negative net margin of 1,451.99%. Equities analysts predict that Chimerix will post ($1.72) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Chimerix Inc. (CMRX) Given Consensus Recommendation of “Hold” by Brokerages” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/23/chimerix-inc-cmrx-given-consensus-recommendation-of-hold-by-brokerages.html.

Chimerix Company Profile

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

5 Day Chart for NASDAQ:CMRX

Receive News & Stock Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related stocks with our FREE daily email newsletter.